BMS-309403

BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of [1][2][3].

Product Specifications

CAS Number

[300657-03-8]

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

FABP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/BMS-309403.html

Purity

99.93

Solubility

DMSO : 175 mg/mL (ultrasonic)

Smiles

O=C(O)COC1=CC(C2=CC=CC=C2N3N=C(C4=CC=CC=C4)C(C5=CC=CC=C5)=C3CC)=CC=C1

Molecular Formula

C31H26N2O3

Molecular Weight

474.55

Precautions

H302, H312, H332

References & Citations

[1]Sulsky R, et al. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP) . Bioorg Med Chem Lett. 2007 Jun 15;17 (12) :3511-5.|[2]Lin W, et al. BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase. PLoS One. 2012;7 (8) :e44570.|[3]Lee MY, et al. Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol. 2011 Apr;162 (7) :1564-76.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Am J Cancer Res. 2019 Oct 1;9 (10) :2140-2155.|Antioxidants (Basel) . 2022 Dec 29;12 (1) :74.|Biochem Pharmacol. 2025 Jul 11:241:117152.|BMC Chem. 2025 Sep 30;19 (1) :270.|Bone Res. 2022 Jun 22;10 (1) :45.|Br J Nutr. 2022 Jan 14;127 (1) :3-11.|Cancer Lett. 2023 Oct 28:575:216403.|Cell Death Dis. 2019 May 16;10 (6) :382. |Cell Mol Life Sci. 2024 Feb 10;81 (1) :83.|Comp Biochem Physiol B Biochem Mol Biol. 2022 Apr-May:259:110715.|Food Chem Toxicol. 2025 Apr 2:115428.|Free Radic Biol Med. 2022 Aug 20:189:42-57.|Indian J Dermatol Venereol Leprol. 2025 Jul 4:1-13.|Int Immunopharmacol. 2023 Sep 2;124 (Pt A) :110859.|Int J Biol Sci. 2021 Oct 11;17 (15) :4207-4222.|Iran J Basic Med Sci. 2022 Oct;25 (10) :1260-1266.|J Med Chem. 2025 Jun 12;68 (11) :11127-11148.|J Proteomics. 2020 Feb 10;212:103570.|Mol Neurobiol. 2025 Nov 21;63 (1) :130.|Neurosci Lett. 2025 Mar 28:853:138199.|Parasitol Res. 2019 Jun;118 (6) :1919-1926. |EMBO Mol Med. 2025 Aug 4.